Search Result

Results for "

α2A-adrenergic receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (13) Adrenergic Receptor (30) Amyloid-β (1) Androgen Receptor (2) Calcium Channel (1) Dopamine Receptor (15) Dopamine Transporter (1) ERK (2) Glucocorticoid Receptor (1) GSK-3 (1) Histone Methyltransferase (1) Imidazoline Receptor (5) Isotope-Labeled Compounds (5) p38 MAPK (2) Reference Standards (4) Serotonin Transporter (1) Tau Protein (1)
By Research Areas:	Cardiovascular Disease (3) Endocrinology (8) Inflammation/Immunology (1) Metabolic Disease (6) Neurological Disease (31)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-75502

Rotigotine 3 Publications Verification N-0923; (-)-N 0437	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease Endocrinology
Rotigotine is a potent dopamine receptor agonist with K_i values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the **α2B-adrenergic receptor**. Rotigotine can be used for parkinson's disease (PD) research .

HY-A0007

Rotigotine Hydrochloride 3 Publications Verification N-0923 Hydrochloride	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease
Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the **α2B-adrenergic receptor, with K_i** of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-B1052

Lofexidine hydrochloride Baq-168; MDL-14042	Adrenergic Receptor Imidazoline Receptor	Neurological Disease Metabolic Disease
Lofexidine hydrochloride (Baq-168) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic *receptor). Lofexidine hydrochloride binds to the α₂A-adrenergic* receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine hydrochloride regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine hydrochloride is applicable to research on opioid addiction and withdrawal .

HY-12716A

BRL-44408 maleate	Adrenergic Receptor ERK p38 MAPK Dopamine Receptor	Cardiovascular Disease Neurological Disease
BRL-44408 maleate is a selective, blood-brain barrier-permeable **α₂A-adrenergic receptor antagonist with a K_i value of 8.56 nM against human targets. BRL-44408 maleate exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65**. BRL-44408 maleate can be used in studies related to acute respiratory distress syndrome, depression and visceral pain .

HY-B1052A

Lofexidine Baq-168 free base; MDL-14042 free base	Imidazoline Receptor Adrenergic Receptor	Neurological Disease Metabolic Disease
Lofexidine (Baq-168 free base) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic *receptor). Lofexidine binds to the α₂A-adrenergic* receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine is applicable to research on opioid addiction and withdrawal .

HY-159639

BAY-2925976	Androgen Receptor	Neurological Disease
BAY-2925976 is an α2C adrenergic receptor (ARα2C) antagonist that can be used for the study of obstructive sleep apnea (OSA) .

HY-15394

(Rac)-Rotigotine hydrochloride N-0437 hydrochloride	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease Endocrinology
(Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the **α2B-adrenergic receptor, with K_i*s of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor* and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-B1052S

Lofexidine-d4 hydrochloride Baq-168-d₄; MDL-14042-d₄	Isotope-Labeled Compounds Imidazoline Receptor Adrenergic Receptor	Neurological Disease Metabolic Disease
Lofexidine-d₄ hydrochloride (Baq-168-d₄) is the deuterium labeled Lofexidine hydrochloride (HY-B1052). Lofexidine hydrochloride (Baq-168) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic *receptor). Lofexidine hydrochloride binds to the α₂A-adrenergic* receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine hydrochloride regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine hydrochloride is applicable to research on opioid addiction and withdrawal .

HY-12716

BRL-44408	Adrenergic Receptor p38 MAPK Dopamine Receptor ERK	Cardiovascular Disease Neurological Disease
BRL-44408 is a selective, blood-brain barrier-permeable **α₂A-adrenergic receptor antagonist with a K_i value of 8.56 nM against human targets. BRL-44408 exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65**. BRL-44408 can be used in studies related to acute respiratory distress syndrome, depression and visceral pain .

HY-19057

Vatinoxan 2 Publications Verification MK-467; L-659066	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
Vatinoxan (MK-467) is an **alpha 2-adrenergic receptor antagonist. The peripheral selectivity of Vatinoxan determines that it has limited penetration across the blood-brain barrier and therefore has low concentrations in the central nervous system. Vatinoxan antagonizes alpha 2-adrenergic receptor** receptors by binding to them, thereby reducing or preventing cardiovascular effects caused by α2-adrenergic agonists. Vatinoxan can be used in studies of cardiovascular effects, sedation and analgesia .

HY-114814

ORM-10921 free base	Adrenergic Receptor	Neurological Disease
ORM-10921 free base is a selective **α-2C adrenergic receptor antagonist with a K_i** of 1.4 nM. ORM-10921 free base displays potent antidepressant and antipsychotic-like effects .

HY-178259

α2AR agonist 2	Adrenergic Receptor	Neurological Disease Inflammation/Immunology
α2AR agonist 2 is a selective **α2B adrenergic receptor antagonist (IC₅₀** = 1.2 µM). α2AR agonist 2 can be used for research on inflammatory pain and neuropathic pain .

HY-15394S

(Rac)-Rotigotine-d7 (hydrochloride) N-0437-d₇ (hydrochloride)	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease Endocrinology
(Rac)-Rotigotine-d₇ (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-A0007S

Rotigotine-d7 hydrochloride N-0923 D7 Hydrochloride	Isotope-Labeled Compounds Dopamine Receptor	Neurological Disease
Rotigotine-d₇ (N-0923-d₇) hydrochloride is the deuterium labeled Rotigotine(HY-75502). Rotigotine is a potent dopamine receptor agonist with K_i values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research.

HY-U00244

Benzquinamide P2647; BZQ; Benzoquinamide	Adrenergic Receptor Dopamine Receptor	Metabolic Disease
Benzquinamide (P2647; BZQ; Benzoquinamide) is an orally active binder of dopamine receptors and **adrenergic receptors. Benzquinamide specifically targets dopamine D2, D3, D4** receptors and α-2A, α-2B, α-2C adrenergic receptors. Benzquinamide regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis .

HY-B1052R

Lofexidine hydrochloride (Standard) Baq-168 (Standard); MDL-14042 (Standard)	Adrenergic Receptor Reference Standards	Neurological Disease Metabolic Disease
Lofexidine (Baq-168) hydrochloride Standard is the analytical standard of Lofexidine hydrochloride (HY-B1052). This product is intended for research and analytical applications. Lofexidine hydrochloride (Baq-168) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic *receptor). Lofexidine hydrochloride binds to the α₂A-adrenergic* receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine hydrochloride regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine hydrochloride is applicable to research on opioid addiction and withdrawal .

HY-B1052S1

Lofexidine-d4 Baq-168 free base-d₄; MDL-14042 free base-d₄	Isotope-Labeled Compounds Imidazoline Receptor Adrenergic Receptor	Neurological Disease Metabolic Disease
Lofexidine-d₄ (Baq-168 free base-d₄) is deuterium labeled Lofexidine (HY-B1052A). Lofexidine (Baq-168 free base) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic *receptor). Lofexidine binds to the α₂A-adrenergic* receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine is applicable to research on opioid addiction and withdrawal .

HY-105412A

RU 52583	Adrenergic Receptor	Neurological Disease
RU 52583 is an oral bioactive antagonist of **alpha 2-adrenergic receptor**. RU 52583 possesses cognition-enhancing properties in rats with damage to the septohippocampal system .

HY-12715S

Yohimbine-13C,d3 1 Publications Verification	Adrenergic Receptor	Neurological Disease Endocrinology
Yohimbine- ¹³C,d₃ is the ¹³C- and deuterium labeled Yohimbine. Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC50 of 0.6 μM.

HY-182597

Tracizoline	Imidazoline Receptor 5-HT Receptor Adrenergic Receptor	Neurological Disease
Tracizoline is an orally active I2-imidazoline receptor agonist. Tracizoline functionally modulates I2-imidazoline receptors, regulates hippocampal FADD cell fate adaptor, attenuates mechanical and thermal hyperalgesia, activates **α₂A-adrenergic receptors** with very weak partial agonism, and induces antidepressant-like activity via 5-HT₁A receptor activation. Tracizoline can be used for the research of inflammatory pain, neuropathic pain, and depression .

HY-15394A

(Rac)-Rotigotine N-0437	Adrenergic Receptor 5-HT Receptor Dopamine Receptor	Neurological Disease Endocrinology
(Rac)-Rotigotine (N-0437) is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the **α2B-adrenergic receptor, with K_i*s of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor* and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-A0007R

Rotigotine Hydrochloride (Standard) N-0923 Hydrochloride (Standard)	Reference Standards Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease
Rotigotine (Hydrochloride) (Standard) is the analytical standard of Rotigotine (Hydrochloride). This product is intended for research and analytical applications. Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the **α2B-adrenergic receptor, with K_i** of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-W042920A

TDIQ hydrochloride	Adrenergic Receptor	Neurological Disease
TDIQ hydrochloride is an analog of Amphetamine with high affinity for α2-adrenergic receptor. TDIQ hydrochloride is a selective α2-adrenoceptor ligand with the K_i values of 75 nM, 95 nM, and 65 nM for α2A-, α2B-, and α2C-adrenergic receptors, respectively .

HY-15394S1

(Rac)-Rotigotine-d3 hydrochloride N-0437-d3 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor Dopamine Receptor 5-HT Receptor	Endocrinology
(Rac)-Rotigotine-d₃ hydrochloride is a deuterium labeled (Rac)-Rotigotine (hydrochloride) (HY-15394). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the **α2B-adrenergic receptor, with K_i*s of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor* and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-15394R

(Rac)-Rotigotine hydrochloride (Standard) N-0437 hydrochloride (Standard)	Dopamine Receptor Adrenergic Receptor 5-HT Receptor Reference Standards	Neurological Disease Endocrinology
(Rac)-Rotigotine (hydrochloride) (Standard) is the analytical standard of (Rac)-Rotigotine (hydrochloride). This product is intended for research and analytical applications. (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-75502R

Rotigotine (Standard) N-0923 (Standard); (-)-N 0437 (Standard)	Reference Standards Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease Endocrinology
Rotigotine (Standard) is the analytical standard of Rotigotine. This product is intended for research and analytical applications. Rotigotine is a potent dopamine receptor agonist with K_i values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the **α2B-adrenergic receptor**. Rotigotine can be used for parkinson's disease (PD) research .

HY-U00244A

Benzquinamide hydrochloride P2647 hydrochloride; BZQ hydrochloride; Benzoquinamide hydrochloride	Adrenergic Receptor Dopamine Receptor	Neurological Disease
Benzquinamide (P2647; BZQ; Benzoquinamide) hydrochloride is an orally active binder of dopamine receptors and **adrenergic receptors. Benzquinamide hydrochloride specifically targets dopamine D2, D3, D4** receptors and α-2A, α-2B, α-2C adrenergic receptors. Benzquinamide hydrochloride regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide hydrochloride has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide hydrochloride can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis .

HY-103117

S 32212 hydrochloride	5-HT Receptor	Neurological Disease
S 32212 hydrochloride is an inverse agonist of 5-HT receptors 5-HT2(CINI) and 5-HT2(CVSV) (Kis=6.6, 8.9 nM) and an antagonist of 5-HT2A and **α2β-adrenergic receptors (Ki=5.8, 5.8 nM). S 32212 hydrochloride can reduce the binding of GTPγS** to Gαq, and reduce the activity of phospholipase C (PLC) in HEK293 cells expressing 5-HT2(CINI) receptor and CHO cells expressing 5-HT2(CVSV) receptor (EC₅₀=38 and 18.6 nM, respectively). S 32212 hydrochloride (2.5 mg/kg) reduces 5-HT receptor agonist-induced head twitches and penile erections in mice and rats. S 32212 hydrochloride (10, 40 mg/kg) reduces immobility time in the forced swim test and marble burying behavior in mice and rats, exerting antidepressant and anxiolytic activities.

HY-103216A

RWJ52353 hydrochloride	Adrenergic Receptor	Neurological Disease
RWJ-52353 hydrochloride is an orally potent, highly selective α2D adrenergic receptor agonist (Ki: 1.5 nM) with potential analgesic effects. RWJ-52353 hydrochloride demonstrated analgesic activity in abdominal tests in rats and mice, and improved agitation in mice in the hot plate test and tail flick test. RWJ-52353 hydrochloride also regulates the organic cation transporter (OCT) subtype, inhibiting rOCT1 and rOCT2 with IC₅₀s of 100 μM and 20 μM respectively; it also activates rOCT3, affecting [3H]-1- in cells. Methyl-4-phenylpyridinium ([3H]MPP) transport .

HY-100323

AGN-201781	Adrenergic Receptor	Neurological Disease
AGN-201781 is an orally active **α-2B adrenergic receptor** agonist. AGN-201781 can be used in studies related to neuropathic pain .

HY-181878

Z8779877149 Z7149	Serotonin Transporter Adrenergic Receptor 5-HT Receptor	Neurological Disease
Z8779877149 (Z7149) is a blood-brain barrier-permeable multi-target ligand that targets SERT (K_i=198 nM), *α2A* adrenergic receptor (K_i=180 nM; EC₅₀=440 nM) and 5-HT_2A receptor (EC₅₀=172 nM, E_max=76%). Z8779877149 inhibits 5-HT reuptake and activates G_i and Gq protein signaling pathways, respectively. Z8779877149 effectively alleviates pain responses as well as depression- and anxiety-like behaviors, while exhibiting favorable safety without inducing sedation or motor impairment. Z8779877149 is available for the research of pain, depression and anxiety disorders .

HY-182091

CYD-1-79	5-HT Receptor Dopamine Receptor Dopamine Transporter Adrenergic Receptor Calcium Channel	Neurological Disease
CYD-1-79 is a selective positive allosteric modulator of 5-HT2C receptor. CYD-1-79 potentiates 5-HT-evoked intracellular calcium release via a topographically distinct allosteric site. CYD-1-79 shows significant inhibition of binding at dopamine D3 receptor, DAT, and *α2A/α2B* adrenergic receptors. CYD-1-79 modulates 5-HT2C receptor-mediated spontaneous ambulation in rodents and synergizes with a low dose of a 5-HT2C receptor agonist. CYD-1-79 attenuates relapse vulnerability of psychoactive substance in a rodent self-administration model. CYD-1-79 can be used for the research of neurological disease .

HY-W657887

GSK-3β/G9a-IN-1	Histone Methyltransferase GSK-3 Tau Protein Amyloid-β Glucocorticoid Receptor Androgen Receptor Adrenergic Receptor	Neurological Disease
GSK-3β/G9a-IN-1 (Compound T2) is an orally active, selective, blood-brain-barrier permeable, competitive G9a (substrate-competitive, IC₅₀: 1.1 μM) and GSK-3β (ATP competitive, IC₅₀: 0.8 μM) inhibitor. GSK-3β/G9a-IN-1 is a potent H3K9me2 inhibitor that reshapes chromatin landscape. GSK-3β/G9a-IN-1 lowers tau phosphorylation, reduces Aβ aggregation. GSK-3β/G9a-IN-1 displays inhibition toward glucocorticoid receptor, androgen receptor, and **alpha-2A adrenergic receptor. GSK-3β/G9a-IN-1 also upregulates SAGA complex members such as Eny2 and Sgf29**. GSK-3β/G9a-IN-1 markedly improves memory, restores social behaviors, and increases synaptic complexity in late-onset Alzheimer’s disease .

Cat. No.	Product Name	Chemical Structure

HY-B1052S

Lofexidine-d4 hydrochloride
Lofexidine-d₄ hydrochloride (Baq-168-d₄) is the deuterium labeled Lofexidine hydrochloride (HY-B1052). Lofexidine hydrochloride (Baq-168) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic *receptor). Lofexidine hydrochloride binds to the α₂A-adrenergic* receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine hydrochloride regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine hydrochloride is applicable to research on opioid addiction and withdrawal .

Lofexidine-d4 hydrochloride

Lofexidine-d₄ hydrochloride (Baq-168-d₄) is the deuterium labeled Lofexidine hydrochloride (HY-B1052). Lofexidine hydrochloride (Baq-168) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic receptor). Lofexidine hydrochloride binds to the α₂A-adrenergic receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine hydrochloride regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine hydrochloride is applicable to research on opioid addiction and withdrawal .

HY-15394S

(Rac)-Rotigotine-d7 (hydrochloride)
(Rac)-Rotigotine-d₇ (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

(Rac)-Rotigotine-d7 (hydrochloride)

(Rac)-Rotigotine-d₇ (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-A0007S

Rotigotine-d7 hydrochloride
Rotigotine-d₇ (N-0923-d₇) hydrochloride is the deuterium labeled Rotigotine(HY-75502). Rotigotine is a potent dopamine receptor agonist with K_i values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research.

Rotigotine-d7 hydrochloride

Rotigotine-d₇ (N-0923-d₇) hydrochloride is the deuterium labeled Rotigotine(HY-75502). Rotigotine is a potent dopamine receptor agonist with K_i values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research.

HY-B1052S1

Lofexidine-d4
Lofexidine-d₄ (Baq-168 free base-d₄) is deuterium labeled Lofexidine (HY-B1052A). Lofexidine (Baq-168 free base) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic *receptor). Lofexidine binds to the α₂A-adrenergic* receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine is applicable to research on opioid addiction and withdrawal .

Lofexidine-d4

Lofexidine-d₄ (Baq-168 free base-d₄) is deuterium labeled Lofexidine (HY-B1052A). Lofexidine (Baq-168 free base) is an orally active agonist of the imidazoline I1 receptor (imidazoline I1 receptor) (Ki: 1.9 nM) and α₂-adrenergic receptor (α2-adrenergic receptor). Lofexidine binds to the α₂A-adrenergic receptor, reduces sympathetic outflow, lowers blood pressure, and exhibits vasoconstrictive effects. Lofexidine regulates the expression of c-fos and alleviates opioid withdrawal symptoms. Lofexidine is applicable to research on opioid addiction and withdrawal .

HY-12715S

Yohimbine-13C,d3 1 Publications Verification
Yohimbine- ¹³C,d₃ is the ¹³C- and deuterium labeled Yohimbine. Yohimbine is a potent and relatively nonselective alpha 2-adrenergic receptor (AR) antagonist, with IC50 of 0.6 μM.

HY-15394S1

(Rac)-Rotigotine-d3 hydrochloride
(Rac)-Rotigotine-d₃ hydrochloride is a deuterium labeled (Rac)-Rotigotine (hydrochloride) (HY-15394). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the **α2B-adrenergic receptor, with K_i*s of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor* and D2, D5, D4 receptors, and dopamine D1 receptor.

(Rac)-Rotigotine-d3 hydrochloride

(Rac)-Rotigotine-d₃ hydrochloride is a deuterium labeled (Rac)-Rotigotine (hydrochloride) (HY-15394). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_is of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: